Merck's Keytruda fails to improve survival in phase 3 head and neck ... - Pharmaceutical Business Review

Pharmaceutical Business Review

Merck's Keytruda fails to improve survival in phase 3 head and neck ... Pharmaceutical Business Review Merck's anti-PD-1 therapy Keytruda (pembrolizumab) failed to improve overall survival (OS) in a pivotal phase 3 trial in head and neck squamous cell c. Keytruda fails confirmatory trial, but Merck says FDA will not pull ...The Pharma Letter (registration) Healthcare Giants In Focus; Pfizer Inc. (PFE) and Merck & Co., Inc ...Investing News Update all 3 news articles »

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2tEbJYT
via IFTTT